SCM
CLDX icon

Sterling Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Sterling Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Sell
522
-1,648
-76% -$53.2K ﹤0.01% 1900
2026
Q1 		$68.8K Sell
2,170
-1,639
-43% -$44.7K ﹤0.01% 1517
2025
Q4 		$103K Sell
3,809
-726
-16% -$19.1K ﹤0.01% 1517
2025
Q3 		$117K Buy
4,535
+2,767
+157% +$64.1K ﹤0.01% 1479
2025
Q2 		$36K Buy
1,768
+1,509
+583% +$29.4K ﹤0.01% 1593
2025
Q1 		$4.7K Sell
259
-175
-40% -$3.91K ﹤0.01% 2193
2024
Q4 		$11K Buy
434
+336
+343% +$9.13K ﹤0.01% 2119
2024
Q3 		$3.33K Buy
+98
New +$3.73K ﹤0.01% 1939

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's CLDX Position: Q2 2026 in Review

Sterling Capital Management reduced its Celldex Therapeutics (CLDX) stake by 76% in Q2 2026, selling an estimated $53.2K and leaving 522 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

Sterling Capital Management first reported a position in CLDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $117K in Q3 2025. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Sterling Capital Management held 522 shares of Celldex Therapeutics worth $19.4K as of Q2 2026.
  • Sterling Capital Management sold 1,648 Celldex Therapeutics shares in Q2 2026, an estimated $53.2K.
  • Celldex Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1900 holding.
  • Sterling Capital Management first reported a position in Celldex Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Celldex Therapeutics position peaked at $117K in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.